Results 131 to 140 of about 2,650 (185)

Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk. [PDF]

Int J Retina Vitreous
Antonietti M, Mercado C, Smiddy WE, Schwartz SG.   +3 more
europepmc   +1 more source

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Letter]. [PDF]

Clin Ophthalmol
Elsaddig M.
europepmc   +1 more source

"Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema". [PDF]

Int J Retina Vitreous
Hansraj S, Narula R, Raval VR, Narayanan R, Tyagi M.   +4 more
europepmc   +1 more source

Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease? [PDF]

, 2022
Chia, Mark A, Keane, Pearse A
core  

Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. [PDF]

Ophthalmol Ther
Kojima H, Yamashita A, Nakano Y, Booka A, Tatara Y, Yamada T, Akimitsu J, Miyoshi Y, Osaka R, Suzuma K.   +9 more
europepmc   +1 more source

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Response to Letter]. [PDF]

Clin Ophthalmol
Chakraborty S, Sheth JU, Ganguly S, Reddy R.   +3 more
europepmc   +1 more source

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. [PDF]

Invest Ophthalmol Vis Sci
Kato N, Haruta M, Arai R, Nagae A, Sato K, Furushima K, Yoshida S.   +6 more
europepmc   +1 more source

Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Age-Related Macular Degeneration: Multicenter Real-World Outcomes. [PDF]

Clin Ophthalmol
Hejsek L, Hrevuš M, Burova M, Beran D, Cyžová Z, Penčák M, Pařilová T, Liláková D, Veith M.   +8 more
europepmc   +1 more source

Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance. [PDF]

PLoS One
Yoshinaga A, Kitamoto K, Aoki S, Terao R, Inoue T, Obata R, Azuma K.   +6 more
europepmc   +1 more source